PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
3.14%
ROE exceeding 1.5x Healthcare median of 0.93%. Joel Greenblatt would check if high returns reflect a sustainable advantage.
-1764.67%
Negative ROA while Healthcare median is 0.00%. Seth Klarman would consider if assets are underutilized or if it’s a distressed opportunity.
5.66%
ROCE exceeding 1.5x Healthcare median of 0.78%. Joel Greenblatt would look for a high return on incremental capital.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.